Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

Kura Oncology (KURA) Financials

Kura Oncology logo
$7.75 -0.32 (-4.00%)
As of 01:08 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Kura Oncology

Annual Income Statements for Kura Oncology

This table shows Kura Oncology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -136 -153 -174
Consolidated Net Income / (Loss)		 -136 -153 -174
Net Income / (Loss) Continuing Operations		 -136 -153 -174
Total Pre-Tax Income 		-136 -153 -172
Total Operating Income		 -140 -166 -193
Total Gross Profit		 0.00 0.00 54
Total Revenue		 0.00 0.00 54
Operating Revenue		 0.00 0.00 54
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 140 166 247
Selling, General & Admin Expense		 47 51 77
Research & Development Expense		 93 115 170
Total Other Income / (Expense), net		 4.03 13 21
Interest Expense		 0.23 1.55 1.62
Interest & Investment Income		 4.25 15 23
Income Tax Expense		 0.00 0.00 2.02
Basic Earnings per Share		 ($2.03) ($2.08) ($2.02)
Weighted Average Basic Shares Outstanding		 66.99M 73.23M 86.16M
Diluted Earnings per Share		 ($2.03) ($2.08) ($2.02)
Weighted Average Diluted Shares Outstanding		 66.99M 73.23M 86.16M
Weighted Average Basic & Diluted Shares Outstanding		 68.44M 76.14M 80.75M

Quarterly Income Statements for Kura Oncology

This table shows Kura Oncology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -36 -33 -34 -37 -37 -44 -50 -50 -53 -21
Consolidated Net Income / (Loss)		 -36 -33 -34 -37 -39 -43 -50 -51 -54 -19
Net Income / (Loss) Continuing Operations		 -36 -33 -34 -37 -39 -43 -50 -51 -54 -19
Total Pre-Tax Income 		-36 -33 -34 -37 -39 -43 -50 -51 -54 -17
Total Operating Income		 -37 -35 -37 -40 -42 -47 -54 -56 -60 -22
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 54
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 54
Total Operating Expenses		 37 35 37 40 42 47 54 56 60 76
Selling, General & Admin Expense		 12 12 11 12 13 14 18 17 18 24
Research & Development Expense		 25 23 25 28 29 33 36 40 42 52
Total Other Income / (Expense), net		 1.09 2.04 2.50 2.83 3.87 3.98 4.93 5.57 5.48 5.26
Interest Expense		 0.00 0.23 0.36 0.39 0.40 0.39 0.40 0.41 0.41 0.40
Interest & Investment Income		 1.09 2.27 2.86 3.22 4.28 4.37 5.33 5.97 5.89 5.66
Basic Earnings per Share		 ($0.53) ($0.49) ($0.50) ($0.53) ($0.50) ($0.55) ($0.59) ($0.59) ($0.63) ($0.21)
Weighted Average Basic Shares Outstanding		 66.89M 66.99M 68.40M 69.80M 77.24M 73.23M 83.91M 86.64M 86.95M 86.16M
Diluted Earnings per Share		 ($0.53) ($0.49) ($0.50) ($0.53) ($0.50) ($0.55) ($0.59) ($0.59) ($0.63) ($0.21)
Weighted Average Diluted Shares Outstanding		 66.89M 66.99M 68.40M 69.80M 77.24M 73.23M 83.91M 86.64M 86.95M 86.16M
Weighted Average Basic & Diluted Shares Outstanding		 66.90M 68.44M 68.44M 74.24M 74.27M 76.14M 76.18M 76.63M 77.76M 80.75M

Annual Cash Flow Statements for Kura Oncology

This table details how cash moves in and out of Kura Oncology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -39 -14 187
Net Cash From Operating Activities		 -110 -125 134
Net Cash From Continuing Operating Activities		 -110 -125 134
Net Income / (Loss) Continuing Operations		 -136 -153 -174
Consolidated Net Income / (Loss)		 -136 -153 -174
Depreciation Expense		 0.76 0.85 0.85
Amortization Expense		 1.68 -8.94 -13
Non-Cash Adjustments To Reconcile Net Income		 27 27 35
Changes in Operating Assets and Liabilities, net		 -3.55 8.50 285
Net Cash From Investing Activities		 33 16 -102
Net Cash From Continuing Investing Activities		 33 16 -102
Purchase of Property, Plant & Equipment		 -0.63 -0.17 -0.47
Purchase of Investments		 -271 -410 -659
Sale and/or Maturity of Investments		 304 426 558
Net Cash From Financing Activities		 39 95 154
Net Cash From Continuing Financing Activities		 39 95 154
Repayment of Debt		 -0.58 0.00 0.00
Issuance of Debt		 10 0.00 0.00
Issuance of Common Equity		 29 95 154
Cash Interest Paid		 0.07 1.06 1.10

Quarterly Cash Flow Statements for Kura Oncology

This table details how cash moves in and out of Kura Oncology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 52 -39 -25 22 -20 8.58 4.19 3.68 4.30 175
Net Cash From Operating Activities		 -21 -27 -36 -26 -29 -34 -49 -43 -43 269
Net Cash From Continuing Operating Activities		 -21 -27 -36 -26 -29 -34 -49 -43 -43 269
Net Income / (Loss) Continuing Operations		 -36 -33 -34 -37 -39 -43 -50 -51 -54 -19
Consolidated Net Income / (Loss)		 -36 -33 -34 -37 -39 -43 -50 -51 -54 -19
Depreciation Expense		 0.19 0.21 0.21 0.21 0.22 0.21 0.23 0.20 0.21 0.20
Amortization Expense		 0.37 -0.58 -1.57 -1.99 -2.77 -2.61 -3.15 -3.42 -3.30 -2.75
Non-Cash Adjustments To Reconcile Net Income		 6.59 7.15 7.02 7.30 7.37 5.70 8.74 8.97 7.82 9.32
Changes in Operating Assets and Liabilities, net		 7.35 -0.19 -7.46 6.03 4.76 5.17 -5.15 2.56 6.24 282
Net Cash From Investing Activities		 72 -47 11 -46 8.56 42 -95 43 46 -95
Net Cash From Continuing Investing Activities		 72 -47 11 -46 8.56 42 -95 43 46 -95
Purchase of Property, Plant & Equipment		 -0.38 -0.01 -0.04 -0.10 -0.02 -0.02 -0.08 -0.02 - -0.37
Purchase of Investments		 -57 -106 -74 -140 -97 -100 -195 -162 -62 -241
Sale and/or Maturity of Investments		 129 59 85 93 105 142 100 205 107 146
Net Cash From Financing Activities		 0.88 35 0.00 94 0.08 0.69 148 3.04 2.20 0.81
Net Cash From Continuing Financing Activities		 0.88 35 0.00 94 0.08 0.69 148 3.04 2.20 0.81
Issuance of Common Equity		 0.88 25 0.00 94 0.08 0.69 148 3.04 2.20 0.81

Annual Balance Sheets for Kura Oncology

This table presents Kura Oncology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 456 449 760
Total Current Assets		 446 432 745
Cash & Equivalents		 52 37 224
Short-Term Investments		 386 387 503
Prepaid Expenses		 8.44 8.52 17
Plant, Property, & Equipment, net		 2.54 1.86 1.68
Total Noncurrent Assets		 7.34 15 14
Other Noncurrent Operating Assets		 7.34 15 14
Total Liabilities & Shareholders' Equity		 456 449 760
Total Liabilities		 36 52 347
Total Current Liabilities		 24 35 79
Short-Term Debt		 - 0.00 2.61
Accounts Payable		 22 34 50
Current Deferred Revenue		 - 0.00 24
Other Current Liabilities		 2.32 1.51 1.88
Total Noncurrent Liabilities		 12 16 268
Long-Term Debt		 9.16 9.33 6.92
Noncurrent Deferred Revenue		 - 0.00 254
Other Noncurrent Operating Liabilities		 2.81 7.07 6.99
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 420 397 414
Total Preferred & Common Equity		 420 397 414
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 420 397 414
Common Stock		 997 1,120 1,308
Retained Earnings		 -569 -721 -895
Accumulated Other Comprehensive Income / (Loss)		 -8.03 -1.27 0.76

Quarterly Balance Sheets for Kura Oncology

This table presents Kura Oncology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 448 426 495 474 554 515 479
Total Current Assets		 436 416 486 460 538 500 463
Cash & Equivalents		 91 27 49 29 42 45 49
Short-Term Investments		 337 379 428 424 486 446 406
Prepaid Expenses		 8.62 11 8.67 7.32 11 8.25 7.89
Plant, Property, & Equipment, net		 2.73 2.37 2.25 2.06 1.71 1.52 1.32
Total Noncurrent Assets		 8.86 7.16 6.84 12 14 14 14
Other Noncurrent Operating Assets		 8.86 7.16 6.84 12 14 14 14
Total Liabilities & Shareholders' Equity		 448 426 495 474 554 515 479
Total Liabilities		 28 31 35 44 49 49 55
Total Current Liabilities		 25 19 24 28 32 33 40
Short-Term Debt		 - - - - - 0.85 1.72
Accounts Payable		 22 17 22 26 31 31 37
Other Current Liabilities		 2.30 2.33 2.35 1.68 1.36 1.47 1.69
Total Noncurrent Liabilities		 3.62 12 11 16 17 16 15
Long-Term Debt		 - 9.20 9.24 9.29 9.38 8.58 7.76
Other Noncurrent Operating Liabilities		 3.62 2.36 1.92 7.02 7.18 7.02 6.94
Total Equity & Noncontrolling Interests		 420 395 460 430 505 466 424
Total Preferred & Common Equity		 420 395 460 430 505 466 424
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 420 395 460 430 505 466 424
Common Stock		 965 1,004 1,105 1,112 1,277 1,288 1,299
Retained Earnings		 -536 -603 -640 -679 -771 -822 -876
Accumulated Other Comprehensive Income / (Loss)		 -9.42 -5.90 -5.22 -3.54 -0.82 -0.46 1.12

Annual Metrics And Ratios for Kura Oncology

This table displays calculated financial ratios and metrics derived from Kura Oncology's official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -9.14% -26.54% -17.87%
EBIT Growth		 -6.56% -18.55% -16.52%
NOPAT Growth		 -6.56% -18.55% -16.52%
Net Income Growth		 -4.12% -12.36% -13.99%
EPS Growth		 -3.05% -2.46% 2.88%
Operating Cash Flow Growth		 -5.27% -13.41% 207.61%
Free Cash Flow Firm Growth		 -5.24% -6.51% 241.38%
Invested Capital Growth		 24.69% -102.97% -1,653.30%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -3.21% -8.51% 10.55%
EBIT Q/Q Growth		 -1.54% -7.53% 11.18%
NOPAT Q/Q Growth		 -1.54% -7.53% 11.18%
Net Income Q/Q Growth		 -0.27% -6.77% 11.93%
EPS Q/Q Growth		 0.49% -2.97% 14.41%
Operating Cash Flow Q/Q Growth		 -2.96% -6.65% 179.42%
Free Cash Flow Firm Q/Q Growth		 -2.81% -4.41% 205.63%
Invested Capital Q/Q Growth		 -4.84% -29.81% -1,279.49%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% 0.00% -380.39%
Operating Margin		 0.00% 0.00% -358.55%
EBIT Margin		 0.00% 0.00% -358.55%
Profit (Net Income) Margin		 0.00% 0.00% -322.89%
Tax Burden Percent		 100.00% 100.00% 101.17%
Interest Burden Percent		 97.12% 92.06% 89.01%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -29.31% -37.34% -42.91%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -31.96%
Return on Assets (ROA)		 0.00% 0.00% -28.78%
Return on Common Equity (ROCE)		 -29.31% -37.34% -42.91%
Return on Equity Simple (ROE_SIMPLE)		 -32.32% -38.42% -42.06%
Net Operating Profit after Tax (NOPAT)		 -98 -116 -135
NOPAT Margin		 0.00% 0.00% -250.98%
Net Nonoperating Expense Percent (NNEP)		 -8.01% -8.67% -6.84%
Return On Investment Capital (ROIC_SIMPLE)		 -22.80% -28.54% -31.96%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 143.11%
R&D to Revenue		 0.00% 0.00% 315.44%
Operating Expenses to Revenue		 0.00% 0.00% 458.55%
Earnings before Interest and Taxes (EBIT)		 -140 -166 -193
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -137 -174 -205
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.98 2.69 1.64
Price to Tangible Book Value (P/TBV)		 1.98 2.69 1.64
Price to Revenue (P/Rev)		 0.00 0.00 12.57
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.02 0.02 0.02
Long-Term Debt to Equity		 0.02 0.02 0.02
Financial Leverage		 -1.02 -1.03 -1.40
Leverage Ratio		 1.07 1.11 1.49
Compound Leverage Factor		 1.04 1.02 1.33
Debt to Total Capital		 2.13% 2.30% 2.25%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.62%
Long-Term Debt to Total Capital		 2.13% 2.30% 1.63%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 97.87% 97.70% 97.75%
Debt to EBITDA		 -0.07 -0.05 -0.05
Net Debt to EBITDA		 3.12 2.38 3.50
Long-Term Debt to EBITDA		 -0.07 -0.05 -0.03
Debt to NOPAT		 -0.09 -0.08 -0.07
Net Debt to NOPAT		 4.38 3.57 5.31
Long-Term Debt to NOPAT		 -0.09 -0.08 -0.05
Altman Z-Score		 12.18 10.00 -0.19
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 18.56 12.26 9.46
Quick Ratio		 18.21 12.02 9.24
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -101 -107 152
Operating Cash Flow to CapEx		 -17,581.79% -74,300.00% 28,456.99%
Free Cash Flow to Firm to Interest Expense		 -439.77 -69.24 93.66
Operating Cash Flow to Interest Expense		 -480.62 -80.58 82.96
Operating Cash Flow Less CapEx to Interest Expense		 -483.35 -80.69 82.67
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.09
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 30.43
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -8.55 -17 -304
Invested Capital Turnover		 0.00 0.00 -0.34
Increase / (Decrease) in Invested Capital		 2.80 -8.80 -287
Enterprise Value (EV)		 401 653 -41
Market Capitalization		 830 1,068 677
Book Value per Share		 $6.28 $5.35 $5.32
Tangible Book Value per Share		 $6.28 $5.35 $5.32
Total Capital		 429 407 423
Total Debt		 9.16 9.33 9.52
Total Long-Term Debt		 9.16 9.33 6.92
Net Debt		 -429 -415 -718
Capital Expenditures (CapEx)		 0.63 0.17 0.47
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -16 -27 -59
Debt-free Net Working Capital (DFNWC)		 422 397 669
Net Working Capital (NWC)		 422 397 666
Net Nonoperating Expense (NNE)		 38 37 39
Net Nonoperating Obligations (NNO)		 -429 -415 -718
Total Depreciation and Amortization (D&A)		 2.44 -8.09 -12
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -108.89%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 1,241.07%
Net Working Capital to Revenue		 0.00% 0.00% 1,236.23%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($2.03) ($2.08) ($2.02)
Adjusted Weighted Average Basic Shares Outstanding		 66.99M 73.23M 86.16M
Adjusted Diluted Earnings per Share		 ($2.03) ($2.08) ($2.02)
Adjusted Weighted Average Diluted Shares Outstanding		 66.99M 73.23M 86.16M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 68.44M 76.14M 80.75M
Normalized Net Operating Profit after Tax (NOPAT)		 -98 -116 -135
Normalized NOPAT Margin		 0.00% 0.00% -250.98%
Pre Tax Income Margin		 0.00% 0.00% -319.15%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -610.76 -107.04 -119.33
NOPAT to Interest Expense		 -427.53 -74.93 -83.53
EBIT Less CapEx to Interest Expense		 -613.50 -107.15 -119.62
NOPAT Less CapEx to Interest Expense		 -430.27 -75.04 -83.82
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Kura Oncology

This table displays calculated financial ratios and metrics derived from Kura Oncology's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -11.45% -13.67% -20.40% -21.61% -24.96% -38.36% -51.23% -42.71% -39.88% 49.16%
EBIT Growth		 -8.66% -6.41% -11.54% -13.22% -16.07% -33.01% -48.91% -41.00% -40.99% 51.98%
NOPAT Growth		 -8.66% -6.41% -11.54% -13.22% -16.07% -33.01% -48.91% -41.00% -40.99% 51.98%
Net Income Growth		 -6.41% -1.13% -4.98% -6.92% -8.73% -29.21% -45.37% -36.75% -40.94% 55.09%
EPS Growth		 -6.00% 2.00% -2.04% -1.92% 5.66% -12.24% -18.00% -11.32% -26.00% 61.82%
Operating Cash Flow Growth		 14.57% -13.54% -11.47% 15.57% -38.16% -29.32% -36.16% -66.02% -49.65% 884.46%
Free Cash Flow Firm Growth		 -7.30% -1.75% 8.54% 37.06% 9.70% 12.70% 3.34% -52.15% -35.54% 1,233.13%
Invested Capital Growth		 15.84% 24.69% 60.34% -950.46% -63.93% -102.97% -734.67% -98.91% -64.99% -1,653.30%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -4.88% 1.39% -6.76% -10.14% -7.77% -9.19% -16.69% -3.94% -5.63% 60.31%
EBIT Q/Q Growth		 -3.57% 3.93% -4.01% -9.40% -6.17% -10.10% -16.45% -3.58% -6.17% 62.50%
NOPAT Q/Q Growth		 -3.57% 3.93% -4.01% -9.40% -6.17% -10.10% -16.45% -3.58% -6.17% 62.50%
Net Income Q/Q Growth		 -2.11% 6.73% -2.88% -9.11% -3.84% -10.84% -15.75% -2.65% -7.02% 64.68%
EPS Q/Q Growth		 -1.92% 7.55% -2.04% -6.00% 5.66% -10.00% -7.27% 0.00% -6.78% 66.67%
Operating Cash Flow Q/Q Growth		 30.75% -26.27% -35.21% 28.59% -13.31% -18.19% -42.37% 12.93% -2.14% 719.55%
Free Cash Flow Firm Q/Q Growth		 17.50% -0.96% -1.80% 25.77% -18.38% 2.40% -12.71% -16.84% -5.45% 915.97%
Invested Capital Q/Q Growth		 -963.10% -4.84% 82.26% -431.11% -65.91% -29.81% 27.03% -26.57% -37.61% -1,279.49%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -46.39%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -41.67%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -41.67%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -35.66%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 111.73%
Interest Burden Percent		 97.02% 94.19% 93.17% 92.93% 90.89% 91.50% 90.95% 90.13% 90.85% 76.59%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -28.42% -29.31% -31.55% -30.77% -33.65% -37.34% -37.34% -39.27% -46.28% -42.91%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.71%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.18%
Return on Common Equity (ROCE)		 -28.42% -29.31% -31.55% -30.77% -33.65% -37.34% -37.34% -39.27% -46.28% -42.91%
Return on Equity Simple (ROE_SIMPLE)		 -32.28% 0.00% -34.78% -30.43% -33.25% 0.00% -33.28% -39.00% -46.62% 0.00%
Net Operating Profit after Tax (NOPAT)		 -26 -25 -26 -28 -30 -33 -38 -39 -42 -16
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -29.17%
Net Nonoperating Expense Percent (NNEP)		 -2.04% -1.80% -1.93% -2.00% -2.04% -2.38% -2.50% -2.39% -2.81% -0.62%
Return On Investment Capital (ROIC_SIMPLE)		 - -5.73% - - - -8.05% - - - -3.71%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 44.67%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 97.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 141.67%
Earnings before Interest and Taxes (EBIT)		 -37 -35 -37 -40 -42 -47 -54 -56 -60 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -36 -36 -38 -42 -45 -49 -57 -60 -63 -25
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.18 1.98 2.12 1.58 1.57 2.69 3.14 3.37 3.53 1.64
Price to Tangible Book Value (P/TBV)		 2.18 1.98 2.12 1.58 1.57 2.69 3.14 3.37 3.53 1.64
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.57
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02
Long-Term Debt to Equity		 0.00 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02
Financial Leverage		 -1.02 -1.02 -1.01 -1.01 -1.03 -1.03 -1.02 -1.03 -1.04 -1.40
Leverage Ratio		 1.06 1.07 1.06 1.06 1.09 1.11 1.09 1.09 1.12 1.49
Compound Leverage Factor		 1.03 1.01 0.99 0.99 0.99 1.01 0.99 0.98 1.01 1.14
Debt to Total Capital		 0.00% 2.13% 2.28% 1.97% 2.11% 2.30% 1.82% 1.98% 2.19% 2.25%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.18% 0.40% 0.62%
Long-Term Debt to Total Capital		 0.00% 2.13% 2.28% 1.97% 2.11% 2.30% 1.82% 1.80% 1.79% 1.63%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 97.87% 97.72% 98.03% 97.89% 97.70% 98.18% 98.02% 97.81% 97.75%
Debt to EBITDA		 0.00 -0.07 -0.06 -0.06 -0.06 -0.05 -0.05 -0.04 -0.04 -0.05
Net Debt to EBITDA		 0.00 3.12 2.76 3.09 2.77 2.38 2.68 2.28 1.95 3.50
Long-Term Debt to EBITDA		 0.00 -0.07 -0.06 -0.06 -0.06 -0.05 -0.05 -0.04 -0.03 -0.03
Debt to NOPAT		 0.00 -0.09 -0.09 -0.09 -0.09 -0.08 -0.07 -0.07 -0.06 -0.07
Net Debt to NOPAT		 0.00 4.38 3.95 4.51 4.11 3.57 4.03 3.44 2.93 5.31
Long-Term Debt to NOPAT		 0.00 -0.09 -0.09 -0.09 -0.09 -0.08 -0.07 -0.06 -0.05 -0.05
Altman Z-Score		 18.49 12.94 15.16 11.43 8.06 10.87 18.29 17.68 14.40 0.55
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 17.64 18.56 21.65 20.32 16.71 12.26 16.67 14.94 11.47 9.46
Quick Ratio		 17.29 18.21 21.10 19.96 16.44 12.02 16.34 14.69 11.28 9.24
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -27 -27 -28 -21 -25 -24 -27 -32 -33 271
Operating Cash Flow to CapEx		 -5,514.44% -221,083.33% -99,644.44% -26,684.38% -145,135.00% -214,425.00% -58,147.62% -265,812.50% 0.00% 72,347.04%
Free Cash Flow to Firm to Interest Expense		 0.00 -119.70 -76.66 -53.52 -60.69 -60.74 -67.77 -77.62 -80.66 672.86
Operating Cash Flow to Interest Expense		 0.00 -115.85 -98.55 -66.19 -71.85 -87.08 -122.72 -104.75 -105.44 667.82
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -115.90 -98.65 -66.44 -71.90 -87.12 -122.93 -104.79 -105.44 666.90
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30.43
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -8.15 -8.55 -1.52 -8.06 -13 -17 -13 -16 -22 -304
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.34
Increase / (Decrease) in Invested Capital		 1.54 2.80 2.31 -7.29 -5.21 -8.80 -11 -7.97 -8.69 -287
Enterprise Value (EV)		 486 401 440 256 234 653 1,066 1,086 1,052 -41
Market Capitalization		 914 830 837 724 677 1,068 1,584 1,569 1,497 677
Book Value per Share		 $6.27 $6.28 $5.77 $6.72 $5.79 $5.35 $6.02 $6.12 $5.53 $5.32
Tangible Book Value per Share		 $6.27 $6.28 $5.77 $6.72 $5.79 $5.35 $6.02 $6.12 $5.53 $5.32
Total Capital		 420 429 404 469 439 407 514 475 433 423
Total Debt		 0.00 9.16 9.20 9.24 9.29 9.33 9.38 9.42 9.47 9.52
Total Long-Term Debt		 0.00 9.16 9.20 9.24 9.29 9.33 9.38 8.58 7.76 6.92
Net Debt		 -428 -429 -397 -468 -443 -415 -518 -482 -446 -718
Capital Expenditures (CapEx)		 0.38 0.01 0.04 0.10 0.02 0.02 0.08 0.02 0.00 0.37
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -16 -16 -8.68 -15 -20 -27 -22 -24 -31 -59
Debt-free Net Working Capital (DFNWC)		 412 422 397 462 432 397 506 467 425 669
Net Working Capital (NWC)		 412 422 397 462 432 397 506 466 423 666
Net Nonoperating Expense (NNE)		 9.89 8.50 8.47 9.17 8.87 10 11 11 12 3.50
Net Nonoperating Obligations (NNO)		 -428 -429 -397 -468 -443 -415 -518 -482 -446 -718
Total Depreciation and Amortization (D&A)		 0.56 -0.38 -1.37 -1.78 -2.55 -2.40 -2.91 -3.22 -3.10 -2.54
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -108.89%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,241.07%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,236.23%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.53) ($0.49) ($0.50) ($0.53) ($0.50) ($0.55) ($0.59) ($0.59) ($0.63) ($0.21)
Adjusted Weighted Average Basic Shares Outstanding		 66.89M 66.99M 68.40M 69.80M 77.24M 73.23M 83.91M 86.64M 86.95M 86.16M
Adjusted Diluted Earnings per Share		 ($0.53) ($0.49) ($0.50) ($0.53) ($0.50) ($0.55) ($0.59) ($0.59) ($0.63) ($0.21)
Adjusted Weighted Average Diluted Shares Outstanding		 66.89M 66.99M 68.40M 69.80M 77.24M 73.23M 83.91M 86.64M 86.95M 86.16M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 66.90M 68.44M 68.44M 74.24M 74.27M 76.14M 76.18M 76.63M 77.76M 80.75M
Normalized Net Operating Profit after Tax (NOPAT)		 -26 -25 -26 -28 -30 -33 -38 -39 -42 -16
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -29.17%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -31.92%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 -153.52 -100.46 -103.37 -105.13 -118.69 -136.81 -138.93 -145.35 -55.72
NOPAT to Interest Expense		 0.00 -107.46 -70.32 -72.36 -73.59 -83.08 -95.77 -97.25 -101.74 -39.00
EBIT Less CapEx to Interest Expense		 0.00 -153.57 -100.55 -103.62 -105.18 -118.73 -137.03 -138.97 -145.35 -56.64
NOPAT Less CapEx to Interest Expense		 0.00 -107.52 -70.42 -72.60 -73.64 -83.12 -95.98 -97.29 -101.74 -39.93
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Kura Oncology (NASDAQ: KURA) has continued to operate with no revenue generation through the last several quarters, reflecting its status as a clinical-stage biopharmaceutical company focused on developing targeted oncology therapies. The company's financial statements over the past four years reveal several notable trends across income, cash flow, and balance sheet metrics.

  • As of Q4 2024, Kura reported a total revenue of approximately $53.9 million, marking its first reported revenue after several quarters of zero revenue. This could indicate initial product or licensing income starting to materialize.
  • Significant cash inflows from operating activities were reported in Q4 2024 ($269 million), a sharp improvement compared to prior quarters that often had negative operating cash flow. This reflects better management of working capital and non-cash adjustments.
  • The company's cash and short-term investments remain robust, with total current assets exceeding $463 million in Q3 2024, down slightly from earlier in the year but still strong to support ongoing research and development.
  • Issuance of common equity remains a consistent source of financing, with meaningful equity raises seen in several quarters during 2023 and 2024, strengthening the balance sheet and providing cash resources.
  • R&D expenses have steadily increased from around $22.7 million in Q4 2022 to over $52 million in Q4 2024, reflecting intensive ongoing drug development efforts common in biotech firms at this stage.
  • SG&A expenses also rose over the period, from approximately $12.5 million in Q4 2022 to $24.1 million in Q4 2024, likely due to expanded corporate operations and preparation for commercialization.
  • Interest income consistently outpaced interest expense, with the company generating several million dollars in investment income, indicative of effective cash management and investment strategy despite negative operating results.
  • Total liabilities have increased somewhat over time but remain moderate relative to equity, indicating a manageable leverage position for a clinical-stage company.
  • Kura Oncology continues to report substantial operating losses, with a net loss attributable to common shareholders of $21.1 million in Q4 2024, although this loss is an improvement over larger losses in previous quarters.
  • Earnings per share remain negative, at around -$0.21 in Q4 2024, consistent with the company's pre-commercial stage and ongoing investment in R&D and SG&A without corresponding revenue growth until recently.
  • Cash flows from operations have been negative or highly volatile in most quarters prior to Q4 2024, indicating the company's reliance on financing activities and investment sales to fund operations.

Summary: Kura Oncology shows early signs of revenue generation in the latest quarter after a multi-year track of development expenses and losses typical for biotech companies. The company maintains a strong liquidity position through substantial cash and investments and financing activities. However, the operating losses and negative earnings per share remain a concern until revenue growth becomes more consistent. Investors should monitor upcoming developments related to product commercialization and clinical trial outcomes that could materially impact the company's financial trajectory.

08/29/25 01:08 PM ETAI Generated. May Contain Errors.

Financials Breakdown Chart

Frequently Asked Questions About Kura Oncology's Financials

When does Kura Oncology's financial year end?

According to the most recent income statement we have on file, Kura Oncology's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Kura Oncology's net income changed over the last 2 years?

Kura Oncology's net income appears to be on an upward trend, with a most recent value of -$173.98 million in 2024, rising from -$135.84 million in 2022. The previous period was -$152.63 million in 2023. Check out Kura Oncology's forecast to explore projected trends and price targets.

What is Kura Oncology's operating income?
Kura Oncology's total operating income in 2024 was -$193.20 million, based on the following breakdown:
  • Total Gross Profit: $53.88 million
  • Total Operating Expenses: $247.08 million
How has Kura Oncology's revenue changed over the last 2 years?

Over the last 2 years, Kura Oncology's total revenue changed from $0.00 in 2022 to $53.88 million in 2024, a change of 5,388,300,000.0%.

How much debt does Kura Oncology have?

Kura Oncology's total liabilities were at $346.52 million at the end of 2024, a 570.7% increase from 2023, and a 861.8% increase since 2022.

How much cash does Kura Oncology have?

In the past 2 years, Kura Oncology's cash and equivalents has ranged from $37.32 million in 2023 to $224.46 million in 2024, and is currently $224.46 million as of their latest financial filing in 2024.

How has Kura Oncology's book value per share changed over the last 2 years?

Over the last 2 years, Kura Oncology's book value per share changed from 6.28 in 2022 to 5.32 in 2024, a change of -15.3%.


Related Companies

This page (NASDAQ:KURA) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...
Brownstone Research | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsoredtc pixel
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...
Crypto 101 Media | Sponsoredtc pixel